Clinical trial GI tumors drug response profiling
Summary
A new clinical trial (NCT07500259) studying drug response profiling in gastrointestinal tumors was registered on ClinicalTrials.gov. This Phase 1/Phase 2 study is investigating how GI tumors respond to drug treatments. The registration provides study details including eligibility criteria, locations, and contact information for potential participants.
What changed
A new clinical trial registration was posted to ClinicalTrials.gov for a study examining drug response profiling in gastrointestinal tumors. The trial (NCT07500259) is classified as Phase 1/Phase 2 and includes standard registration information such as study design, inclusion/exclusion criteria, investigator details, and participating sites.
This is an informational registration with no compliance obligations for regulated entities. Clinical investigators may review eligibility requirements if considering patient referrals. Patients seeking experimental treatments may use this database to identify potential trial participation opportunities.
Source document (simplified)
Show glossary
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ClinicalTrials.gov publishes new changes.